Numaferm Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $57.8K

  • Investors
  • 8

Numaferm General Information

Description

Developer of peptide production technology designed to unlock the potential of peptides, pepteins, and proteins as feedstock. The company's technology uses microorganisms to convert simple nutrients to peptides and offers services like peptide development, custom synthesis and larger-scale production, enabling clients to get helped in the discovery to commercial production of peptides.

Contact Information

Website
www.numaferm.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Merowingerplatz 1a
  • 40225 Dusseldorf
  • Germany
+49 0211 00000000
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Merowingerplatz 1a
  • 40225 Dusseldorf
  • Germany
+49 0211 00000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Numaferm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 23-Oct-2018 $57.8K Completed Generating Revenue
2. Seed Round 11-May-2017 Completed Generating Revenue
1. Grant 01-Oct-2015 Completed Startup
To view Numaferm’s complete valuation and funding history, request access »

Numaferm Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of peptide production technology designed to unlock the potential of peptides, pepteins, and proteins as feeds
Drug Discovery
Dusseldorf, Germany
22 As of 2023
0000000000

00000

nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Du
0000 000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000

000 00

tate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
0000 000000000
Berlin, Germany
00 As of 0000
00.00
000000000 00 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Numaferm Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Twist Bioscience Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
JPT Peptides Technologies (BioNTech) Corporate Backed or Acquired Berlin, Germany 00 00.00 000000000 00 00.00
Feldan Therapeutics Venture Capital-Backed Quebec, Canada 00 000.00 0000000000 000.00
ARVYS Proteins Corporation Trumbull, CT
GenScript Formerly VC-backed Piscataway, NJ 0000 00000 000000000 00000
You’re viewing 5 of 13 competitors. Get the full list »

Numaferm Patents

  • 27

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 17

    Granted

  • 8

    Pending

  • 000

    Expiring in next 12 mo

Numaferm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4339202-A1 Fusion proteins comprising gg repeat sequences ii Pending 16-Sep-2022 0000000000 0
EP-4321618-A1 Variants of tev protease and uses thereof Pending 09-Aug-2022 000000000 0
EP-4308704-A1 Fusion proteins comprising gg repeat sequences Pending 18-Mar-2021 0000000000
US-20240228553-A1 Fusion proteins comprising gg repeat sequences Pending 18-Mar-2021 0000000000
EP-3892290-A1 Variants of hlya and uses thereof Inactive 08-Apr-2020 C07K14/245 0
To view Numaferm’s complete patent history, request access »

Numaferm Executive Team (5)

Name Title Board Seat
Christian Schwarz Ph.D Co-Founder, Managing Director, Chief Executive Officer & Advisor
Christopher Klein Chief Financial Officer,Head of Investor Relations & Managing Director
Detlev Riesner Advisor
Jürgen Schumacher Ph.D Advisor
You’re viewing 4 of 5 executive team members. Get the full list »

Numaferm Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Numaferm Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Horizon 2020 SME Instrument Government 000 0000 000000 0
Bundesministerium für Bildung und Forschung Government Minority 000 0000 000000 0
Detlev Riesner Angel (individual) Minority 000 0000 000000 0
European Investment Fund Fund of Funds Minority 000 0000 000000 0
Evonik Venture Capital Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

Numaferm FAQs

  • When was Numaferm founded?

    Numaferm was founded in 2015.

  • Who is the founder of Numaferm?

    Christian Schwarz Ph.D and Philipp Bürling are the founders of Numaferm.

  • Who is the CEO of Numaferm?

    Christian Schwarz Ph.D is the CEO of Numaferm.

  • Where is Numaferm headquartered?

    Numaferm is headquartered in Dusseldorf, Germany.

  • What is the size of Numaferm?

    Numaferm has 22 total employees.

  • What industry is Numaferm in?

    Numaferm’s primary industry is Drug Discovery.

  • Is Numaferm a private or public company?

    Numaferm is a Private company.

  • What is Numaferm’s current revenue?

    The current revenue for Numaferm is 00000.

  • Who are Numaferm’s investors?

    Horizon 2020 SME Instrument, Bundesministerium für Bildung und Forschung, Detlev Riesner, European Investment Fund, and Evonik Venture Capital are 5 of 8 investors who have invested in Numaferm.

  • Who are Numaferm’s competitors?

    Twist Bioscience, JPT Peptides Technologies (BioNTech), Feldan Therapeutics, ARVYS Proteins, and GenScript are some of the 13 competitors of Numaferm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »